Interventions for treating intrahepatic cholestasis in people with sickle cell disease.
Cochrane Database Syst Rev
; 6: CD010985, 2020 06 22.
Article
in En
| MEDLINE
| ID: mdl-32567054
ABSTRACT
BACKGROUND:
Sickle cell disease is the most common hemoglobinopathy occurring worldwide and sickle cell intrahepatic cholestasis is a complication long recognized in this population. Cholestatic liver diseases are characterized by impaired formation or excretion (or both) of bile from the liver. There is a need to assess the clinical benefits and harms of the interventions used to treat intrahepatic cholestasis in people with sickle cell disease. This is an update of a previously published Cochrane Review.OBJECTIVES:
To assess the benefits and harms of the interventions for treating intrahepatic cholestasis in people with sickle cell disease. SEARCHMETHODS:
We searched the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register, which comprises references identified from comprehensive electronic database searches and handsearching of relevant journals and abstract books of conference proceedings. We also searched the LILACS database (1982 to 21 January 2020), the WHO International Clinical Trials Registry Platform Search Portal and ClinicalTrials.gov (21 January 2020). Date of last search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register 25 November 2019. SELECTION CRITERIA We searched for published or unpublished randomised controlled trials. DATA COLLECTION ANDANALYSIS:
Each author intended to independently extract data, assess the risk of bias of the trials by standard Cochrane methodologies and assess the quality of the evidence using the GRADE criteria; however, no trials were included in the review. MAINRESULTS:
We did not identify any randomised controlled trials. AUTHORS'CONCLUSIONS:
This updated Cochrane Review did not identify any randomised controlled trials assessing interventions for treating intrahepatic cholestasis in people with sickle cell disease. Randomised controlled trials are needed to establish the optimum treatment for this condition.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cholestasis, Intrahepatic
/
Anemia, Sickle Cell
Type of study:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
/
Systematic_reviews
Limits:
Humans
Language:
En
Journal:
Cochrane Database Syst Rev
Journal subject:
PESQUISA EM SERVICOS DE SAUDE
Year:
2020
Document type:
Article
Affiliation country:
Ecuador